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Abstract
Background: Oesophageal cancer is a major clinical problem with a generally poor prognosis. As a result
there has been interest in combining surgery with neoadjuvant chemotherapy to try and improve
outcomes, although the current evidence for benefit is inconsistent. We aimed to compare, in a non-
randomised study, the post-operative complication rate and short and long-term survival of patients who
underwent surgical resection for carcinoma of the oesophagus and types I and II carcinoma of the
oesophago-gastric junction with or without neo-adjuvant chemotherapy.
Methods:  Details of all resections for oesophageal/junctional (types I and II) adenocarcinoma or
squamous cell carcinoma between April 2000 and July 2006 were collected prospectively. Data from
patients with T3 and/or N1 disease who underwent either neoadjuvant chemotherapy (NAC) or not (non-
NAC) were compared. Data were analysed using Kaplan-Meier plots, Mann-Whitney U-test, Cox
Regression modelling, and Chi-squared test with Yates' correction where sample sizes <10.
Results: 167 patients were included (89 NAC and 78 non-NAC). The in-hospital post-operative mortality
rate of the NAC group (n = 2 deaths; 2.2%) was significantly lower (p = 0.045) than the non-NAC group
(n = 6 deaths; 7.7%). Most deaths were due to cardio-respiratory complications; however, there was no
significant difference in rates of chest infections, anastomotic leaks, wound infections, re-operations,
readmission to ITU or overall complications between the two groups. Although both the two-year survival
rate (60.7%) and long-term survival of NAC patients (median survival = 793 days; 95% CI = 390–1196) was
greater than non-NAC patients (two-year survival rate = 48.7%; median survival = 554 days; 95% CI =
246–862 respectively), these differences were not statistically significant.
Conclusion:  This non-randomised study demonstrated that NAC was associated with a significant
reduction in post-operative inpatient mortality rate. Whether this can be explained by a decreased co-
morbidity in NAC patients or a protective phenomenon associated with NAC remains unclear. This study
also demonstrated a greater two-year survival rate and overall median survival time following NAC but
this was not statistically significant.
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Background
Surgery remains the treatment of choice for potentially
curable oesophageal cancer, although long term survival
rates are still poor [1-4]. As a result there has been increas-
ing interest in combining surgery with neo-adjuvant
chemotherapy (NAC) [1,4-6]. The potential benefits of
NAC administration include improvement of swallowing,
resulting in better patient nutrition, and down-staging of
the primary tumour and elimination of micro-metastases,
thus increasing the likelihood of a curative resection.
Randomised controlled trials and meta-analyses investi-
gating the effect of NAC on oesophageal adenocarcinoma
(ACC) and squamous cell carcinoma (SCC) have been
inconsistent [1,4-6]. The MRC OEO2 trial demonstrated
an increase in the two-year survival rate and median sur-
vival duration of patients who received two pre-operative
cycles of cisplatin and 5-fluorouracil (5FU) [4]. However,
another large trial failed to demonstrate a survival advan-
tage with a similar regimen [5]. In the UK, current guide-
lines suggest that pre-operative chemotherapy for ACC or
SCC of the oesophagus and oesophago-gastric junction
(OGJ) (types I and II) should be considered [7].
In April 2000, we began a policy of treating selected
patients in the South-East of Scotland with oesophageal or
Type I/II OJG ACC/SCC with two cycles of pre-operative
cisplatin and 5FU and we report here our results.
Methods
Patients
Details of all patients with oesophageal and OGJ cancer in
the Lothian and Borders area are collected prospectively.
Using this database, we analysed the demographics, post-
operative complication rates and survival rates of those
patients who underwent potentially curative resection of
oesophageal or type I/II OGJ ACC or SCC between April
2000 and July 2006. During this time the indications for
pre-operative chemotherapy were either T3 or N1 disease
without evidence of distant metastases on pre-operative
endoscopic ultrasound, CT or laparoscopic ultrasound
scanning. We compared specifically the data of those
patients with T3 and/or N1 disease who had received neo-
adjuvant chemotherapy (NAC group) with those patients
who did not receive neo-adjuvant chemotherapy either
for personal reasons or medical contra-indications e.g. sig-
nificant co-morbidity, in particular cardiac disease (non-
NAC group). The chemotherapy regimen consisted of 2
pre-operative cycles of 5-FU and cisplatin, given 2 weeks
apart. Surgery followed within 5 weeks. All patients with
oesophageal carcinoma and type I carcinoma of the OGJ
underwent an Ivor Lewis subtotal oesophagectomy with
two field lymphadenectomy. Patients with type II OGJ
carcinoma underwent either the same procedure or an
oesophagogastrectomy through a left thoraco-abdominal
incision, depending on the extent of tumour above and
below the OGJ. This latter group had a level-two abdomi-
nal lymphadenectomy and local clearance of lymph
nodes around the hiatus and up to the level of transection
of the oesophagus. Survival was calculated in days from
the date of endoscopic diagnosis. To investigate the possi-
bility of tumour downstaging by neo-adjuvant chemo-
therapy, pre-operative staging was compared to final
histology for each group. The Scottish Intercollegiate
Guidelines on staging of oesophageal cancer were used
[7].
Statistics
The Statistical Package for Social Services Version 12 was
used to analyse the data. Mann-Whitney U test was used
to compare patient demographics between groups. Chi-
squared test was used to determine any difference in the
rate of post-operative complications between patient
groups. Yates' correction for continuity was applied where
sample size was less than 10. Univariate Kaplan-Meier
analysis was used to assess patient survival in different
patient groups and tumour stages. Any patient variable
associated with a p value of < 0.1 on univariate Kaplan-
Meier analysis was included in a multivariate Cox Regres-
sion model. Statistical significance was set at p < 0.05.
Results
Patient Demographics
The study included 167 patients, 89 of whom received
NAC (NAC group) and 78 who did not (non-NAC group).
There were no significant differences in patient sex,
tumour stage (as determined post-operatively by a Con-
sultant Pathologist) and histological tumour type
between the two patient groups (Table 1). However, the
NAC group were significantly younger than the non-NAC
group (median age 60 yrs; range 30–79 yrs vs median age
65 yrs; range 37–82 yrs; p < 0.01) (Table 1).
Tumour Downstaging
In 75.3% of the NAC patients and 70.5% of the non-NAC
patients, the pre-operative T stage matched the final post-
operative histopathological T stage (p = 0.49). Similarly,
68.5% of the NAC patients and 59.0% of the non-NAC
patients had matching pre- and post-operative N stages (p
= 0.199). Thus, 27.0% of NAC patients and 17.9% of the
non-NAC patients had either been over-staged pre-opera-
tively or, in the case of the NAC patients, had undergone
tumour 'downstaging. (p = 0.17) (Table 2).
Post-Operative Complications
There was no significant difference in the incidence of
anastomotic leaks (NAC: n = 8, 9.0%; non-NAC: n = 8,
10.3%, p = 0.59), wound infections (NAC: n = 8, 9.0%;
non-NAC: n = 4; 5.1%; p = 0.51), chest infections (NAC:
n = 15, 16.9%; non-NAC: n = 17, 21.8%; p = 0.42), re-International Seminars in Surgical Oncology 2007, 4:24 http://www.issoonline.com/content/4/1/24
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admissions to ITU (NAC: n = 10, 11.2%; non-NAC: n =
12, 15.4%; p = 0.31), re-operations (NAC: n = 4, 4.5%;
non-NAC: n = 1, 1.3%; p = 0.31) or overall post-operative
complications (NAC: n = 32, 36.0%; non-NAC: n = 35,
44.9%; p = 0.24) between the two patient groups (Fig. 1).
However, the NAC group did demonstrate a significantly
lower post-operative in-hospital mortality rate (n = 2,
2.2%) compared with the non-NAC group (n = 6, 7.7%; p
= 0.045). Of the 8 patients who died in hospital, 4 died
due to pneumonia (all from the non-NAC group), a fur-
ther 3 died due to cardio-respiratory arrest following a
past history of ischaemic heart disease (2 non-NAC group
and 1 NAC group), and 1 patient died following a signifi-
cant upper gastrointestinal haemorrhage (NAC group).
Patient Survival
Median survival of the NAC group was 793 days (95% CI
= 390–1196 days) compared with 554 days (95% CI =
246–862 days) in the non-NAC group. However, this dif-
ference did not reach statistical significance (p = 0.37)
(Fig. 2). Two year survival rates for the NAC and non-NAC
groups were 60.7% and 48.7% respectively (p = 0.16).
This trend for improved survival in the NAC group was
consistent when data were grouped and analysed by indi-
vidual T and N stages (Figs. 3 &4). Univariate analysis
demonstrated that patient age, sex, histological tumour
type and pre-operative tumour stage did not significantly
affect patient survival. Only post-operative stage as deter-
mined histopathologically affected patient survival signif-
icantly (p < 0.01). A Cox Regression model including
post-operative stage and NAC status was generated, but
this did not demonstrate a significant effect of NAC on the
odds ratio (OR) of patient death (OR = 0.84; 95% CI =
0.55 – 1.27; p = 0.40).
Discussion
Although this non-randomised study of patients undergo-
ing oesophago-gastrectomy demonstrated that the overall
complication rate in those patients not receiving NAC was
greater than those who received NAC, these differences
were not statistically significant and the overall rates are
similar to those observed in other studies [4-6]. Our study
did, however, demonstrate a significantly lower in-hospi-
tal mortality rate in the NAC group compared with the
non-NAC group. The higher post-operative mortality of
the non-NAC group may be attributed to a greater number
of chest infections that, although not statistically signifi-
cant, may have resulted in more systemic compromise in
the non-NAC group, which in turn may have had a higher
co-morbidity. This hypothesis is supported by the obser-
vation that the NAC group was significantly younger than
the non-NAC group (median age 60 vs 65 yrs). Another
possible explanation is that NAC is associated with a pro-
tective pre-conditioning phenomenon, which subse-
quently improves patients' post-operative recovery. A
similar theory has been suggested in transplantation,
where recent studies have demonstrated that by up-regu-
lating the stress protein heme-oxygenase-1, using toxins
such as curcumin, inflammatory injury and cellular apop-
tosis post-transplant are reduced [8,9].
Importantly, NAC administration was associated with
increases in both two-year survival rate and overall
median survival duration, although these increases were
Table 2: The number and percentage of patients whose T stage, N stage or overall stage was predicted pre-operatively to be higher 
than the stage determined post-operatively by histopathological examination.
NAC group (n = 89) Non-NAC group (n = 78) p value
Pre-op T > Post-op T 12 (13.5%) 15 (19.2%) 0.31
Pre-op N > Post-op N 20 (22.5%) 12 (15.4%) 0.25
Overall Pre-op stage > Overall Post-op stage 24 (27.0%) 14 (17.9%) 0.17
Table 1: Demographics of the two patient groups. Age is expressed as medians with ranges in parentheses.
NAC (n = 89) Non-NAC (n = 78) p value
AGE (years) 60 (30–79) 65 (37–82) P < 0.01
SEX Male 70 69 0.09
Female 19 9
STAGE I 3 3 0.92
IIA 20 16
IIB 66
III 50 44
IV 10 9
TYPE Adenocarcinoma 70 19 0.23
Squamous Cell Carcinoma 67 11International Seminars in Surgical Oncology 2007, 4:24 http://www.issoonline.com/content/4/1/24
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not statistically significant. These trends were also seen
when the effect of NAC on specific stages of disease was
examined. Relatively small patient numbers and a lack of
statistical power may simply explain the lack of statistical
significance. However, it is interesting to note that the dif-
ference in median survival duration and 2-year survival
rate between the two treatment groups was greater than
that observed in the MRC OEO2 trial (239 vs 107 days
and 12% vs 9% respectively), a trial which demonstrated
statistical significance [4]. The operative mortality
reported in our study is also lower than that reported in
the MRC OEO2 trial (5% vs 10% respectively). Explana-
tions for the better figures we report may include manage-
ment within a multi-disciplinary team, standardised
staging, agreed treatment protocols and the utilisation of
an experienced surgical team with appropriate ITU sup-
port.
Kaplan-Meier survival curves of NAC and non-NAC patients  with T2 and T3 disease Figure 3
Kaplan-Meier survival curves of NAC and non-NAC 
patients with T2 and T3 disease. (T2/non-NAC: median 
survival: 552 days, 95% CI = 409–695 days; T2/NAC: median 
survival: 565 days, 95% CI = 361–769 days; T3/non-NAC: 
median survival: 554 days, 95% CI = 356–752 days; T3/NAC: 
median survival: 870 days, 95% CI = 407–1333 days; p = 
0.65).
Post-operative complication rates in the two patient groups Figure 1
Post-operative complication rates in the two patient 
groups. (COMPS = overall post-operative complications: 
ANAST LEAKS = anastamotic leaks; CHEST INF = chest 
infections = WOUND INF = wound infections; RE-OP = 
patients who required a 're-operation'; ITU = number of 
patients re-admitted to ITU; DIED IN HOSP = number of 
patients who died in hospital; * = p = 0.045).
Kaplan-Meier survival curves of NAC and non-NAC groups  (p = 0.37) Figure 2
Kaplan-Meier survival curves of NAC and non-NAC groups 
(p = 0.37).International Seminars in Surgical Oncology 2007, 4:24 http://www.issoonline.com/content/4/1/24
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Our results also suggested that NAC may 'downstage'
tumours although this finding was also not statistically
significant. This phenomenon of 'downstaging' may also
be an explanation of the improved survival.
Conclusion
In conclusion, our study demonstrates the successful
regional implementation of NAC in the treatment of
oesophageal cancer, and suggests a trend towards
improved survival following the use of NAC. We have
shown the ability to translate the results of clinical trials
into routine practice and also illustrated the importance
of audits following the introduction of new treatment reg-
imens. Larger patient numbers may be required to show
conclusively a statistically significant improvement in
median survival duration. However, although the differ-
ence in median survival following NAC administration is
not statistically significant in this study, for each individual
patient it is likely to be clinically significant. Finally, the
lower post-operative mortality associated with neoadju-
vant chemotherapy is an interesting observation that war-
rants further basic science investigation.
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